Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide

Phase 2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Recurrent Primary Amyloidosis

Conditions

Recurrent Primary Amyloidosis

Trial Timeline

Aug 25, 2017 → Dec 7, 2023

NCT ID

NCT03252600

About Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide

Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide is a phase 2 stage product being developed by Bristol Myers Squibb for Recurrent Primary Amyloidosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03252600. Target conditions include Recurrent Primary Amyloidosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03252600	Phase 2	UNKNOWN	Aug 25, 2017	Dec 7, 2023	Recurrent Primary Amyloidosis

Competing Products

20 competing products in Recurrent Primary Amyloidosis

See all competitors

Product	Company	Stage	Hype Score
KPL-914	Kiniksa Pharmaceuticals	Phase 2	47
KPL-387	Kiniksa Pharmaceuticals	Phase 2	47
Rilonacept + Placebo	Kiniksa Pharmaceuticals	Phase 3	72
Enzastaurin (LY317615) + Carboplatin	Eli Lilly	Phase 1	33
Zopapogene imadenovec (Zopa)	Precigen	Approved	80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	36
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
Ramucirumab + Pembrolizumab	Eli Lilly	Phase 2	52
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab	Daiichi Sankyo	Phase 1/2	41
Ifinatamab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 1	33
PLX3397	Daiichi Sankyo	Phase 2	52
erlotinib + etoposide	Astellas Pharma	Phase 2	52
Drug Combination Therapy	Sun Pharmaceutical	Phase 2	52
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	52
Eribulin Mesylate	Eisai	Pre-clinical	23
Lenvatinib + Everolimus	Eisai	Phase 1/2	41
E7090	Eisai	Phase 2	52
Lenvatinib	Eisai	Phase 2	52

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved